NYMXF — Nymox Pharmaceutical Cashflow Statement
0.000.00%
Last trade - 00:00- $3.78m
- $3.71m
Annual cashflow statement for Nymox Pharmaceutical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -11.7 | -12.5 | -6.58 | -8.84 | -4.49 |
| Depreciation | |||||
| Non-Cash Items | 2.01 | 2.85 | 0.864 | 3.46 | 0.671 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.314 | -0.14 | 0.495 | 1.32 | 1.22 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -10 | -9.82 | -5.21 | -4.06 | -2.6 |
| Capital Expenditures | -0.013 | -0.006 | 0 | -0.003 | — |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.013 | -0.006 | 0 | -0.003 | — |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 8.42 | 7.04 | 5.78 | 2.73 | 2.6 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -1.63 | -2.78 | 0.573 | -1.33 | 0.004 |